<!doctype html>
<html class="docs-version-current" lang="en" dir="ltr">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<meta name="generator" content="Docusaurus v2.0.0-beta.14">
<link rel="alternate" type="application/rss+xml" href="/build-back-better-breakdown/blog/rss.xml" title="Build Back Better - HR-5376 RSS Feed">
<link rel="alternate" type="application/atom+xml" href="/build-back-better-breakdown/blog/atom.xml" title="Build Back Better - HR-5376 Atom Feed"><title data-react-helmet="true">Part 2 - Prescription Drug Inflation Rebates | Build Back Better - HR-5376</title><meta data-react-helmet="true" name="twitter:card" content="summary_large_image"><meta data-react-helmet="true" property="og:url" content="https://edwardangert.github.io/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2"><meta data-react-helmet="true" name="docusaurus_locale" content="en"><meta data-react-helmet="true" name="docusaurus_version" content="current"><meta data-react-helmet="true" name="docusaurus_tag" content="docs-default-current"><meta data-react-helmet="true" property="og:title" content="Part 2 - Prescription Drug Inflation Rebates | Build Back Better - HR-5376"><meta data-react-helmet="true" name="description" content="SEC. 139101. MEDICARE PART B REBATE BY MANUFACTURERS."><meta data-react-helmet="true" property="og:description" content="SEC. 139101. MEDICARE PART B REBATE BY MANUFACTURERS."><link data-react-helmet="true" rel="icon" href="/build-back-better-breakdown/img/favicon.ico"><link data-react-helmet="true" rel="canonical" href="https://edwardangert.github.io/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2"><link data-react-helmet="true" rel="alternate" href="https://edwardangert.github.io/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2" hreflang="en"><link data-react-helmet="true" rel="alternate" href="https://edwardangert.github.io/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2" hreflang="x-default"><link rel="stylesheet" href="/build-back-better-breakdown/assets/css/styles.d9d837ef.css">
<link rel="preload" href="/build-back-better-breakdown/assets/js/runtime~main.f44b3b35.js" as="script">
<link rel="preload" href="/build-back-better-breakdown/assets/js/main.5dd824db.js" as="script">
</head>
<body>
<script>!function(){function t(t){document.documentElement.setAttribute("data-theme",t)}var e=function(){var t=null;try{t=localStorage.getItem("theme")}catch(t){}return t}();t(null!==e?e:"light")}()</script><div id="__docusaurus">
<div><a href="#" class="skipToContent_OuoZ">Skip to main content</a></div><nav class="navbar navbar--fixed-top"><div class="navbar__inner"><div class="navbar__items"><button aria-label="Navigation bar toggle" class="navbar__toggle clean-btn" type="button" tabindex="0"><svg width="30" height="30" viewBox="0 0 30 30" aria-hidden="true"><path stroke="currentColor" stroke-linecap="round" stroke-miterlimit="10" stroke-width="2" d="M4 7h22M4 15h22M4 23h22"></path></svg></button><a class="navbar__brand" href="/build-back-better-breakdown/"><div class="navbar__logo"><img src="/build-back-better-breakdown/img/logo.svg" alt="My Site Logo" class="themedImage_TMUO themedImage--light_4Vu1"><img src="/build-back-better-breakdown/img/logo.svg" alt="My Site Logo" class="themedImage_TMUO themedImage--dark_uzRr"></div><b class="navbar__title">H.R.5376</b></a><a class="navbar__item navbar__link navbar__link--active" href="/build-back-better-breakdown/docs/intro">Explore the Act</a><a class="navbar__item navbar__link" href="/build-back-better-breakdown/blog">News</a></div><div class="navbar__items navbar__items--right"><a href="https://github.com/EdwardAngert/build-back-better-breakdown" target="_blank" rel="noopener noreferrer" class="navbar__item navbar__link"><span>GitHub<svg width="13.5" height="13.5" aria-hidden="true" viewBox="0 0 24 24" class="iconExternalLink_wgqa"><path fill="currentColor" d="M21 13v10h-21v-19h12v2h-10v15h17v-8h2zm3-12h-10.988l4.035 4-6.977 7.07 2.828 2.828 6.977-7.07 4.125 4.172v-11z"></path></svg></span></a><div class="toggle_iYfV toggle_2i4l toggleDisabled_xj38"><div class="toggleTrack_t-f2" role="button" tabindex="-1"><div class="toggleTrackCheck_mk7D"><span class="toggleIcon_pHJ9">ðŸŒœ</span></div><div class="toggleTrackX_dm8H"><span class="toggleIcon_pHJ9">ðŸŒž</span></div><div class="toggleTrackThumb_W6To"></div></div><input type="checkbox" class="toggleScreenReader_h9qa" aria-label="Switch between dark and light mode"></div></div></div><div role="presentation" class="navbar-sidebar__backdrop"></div></nav><div class="main-wrapper docs-wrapper docs-doc-page"><div class="docPage_lDyR"><button aria-label="Scroll back to top" class="clean-btn theme-back-to-top-button backToTopButton_i9tI" type="button"></button><aside class="docSidebarContainer_0YBq"><div class="sidebar_a3j0"><nav class="menu thin-scrollbar menu_cyFh"><ul class="theme-doc-sidebar-menu menu__list"><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-1 menu__list-item"><a class="menu__link" href="/build-back-better-breakdown/docs/intro">Build Back Better Act Breakdown</a></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-1 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link menu__link--sublist hasHref_TwRn" href="/build-back-better-breakdown/docs/title-1-agriculture/title-1-subtitle-b">Title I - Agriculture</a></div></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-1 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link menu__link--sublist hasHref_TwRn" href="/build-back-better-breakdown/docs/title-2-committee-on-education-and-labor/title-2-subtitle-a/title-2-subtitle-a-part-1">Title II - Committee on Education and Labor</a></div></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-1 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link menu__link--sublist hasHref_TwRn" href="/build-back-better-breakdown/docs/title-3-committee-on-energy-and-commerce/title-3-subtitle-a">Title III - Committee on Energy and Commerce</a></div></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-1 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link menu__link--sublist hasHref_TwRn" href="/build-back-better-breakdown/docs/title-4-committee-on-financial-services/title-4-subtitle-a">Title IV - Committee On Financial Services</a></div></li><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-1 menu__list-item"><a class="menu__link" href="/build-back-better-breakdown/docs/title-5-committee-on-homeland-security">Title V - Committee On Homeland Security</a></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-1 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link menu__link--sublist hasHref_TwRn" href="/build-back-better-breakdown/docs/title-6-committee-on-the-judiciary/title-6-subtitle-a">Title VI - Committee On The Judiciary</a></div></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-1 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link menu__link--sublist hasHref_TwRn" href="/build-back-better-breakdown/docs/title-7-committee-on-natural-resources/title-7-subtitle-a">Title VII - Committee On Natural Resources</a></div></li><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-1 menu__list-item"><a class="menu__link" href="/build-back-better-breakdown/docs/title-8-committee-on-oversight-and-reform">Title VIII - Committee On Oversight And Reform</a></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-1 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link menu__link--sublist hasHref_TwRn" href="/build-back-better-breakdown/docs/title-10-committee-on-small-business/title-10-definitions">Title X - Committee On Small Business</a></div></li><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-1 menu__list-item"><a class="menu__link" href="/build-back-better-breakdown/docs/title-11-committee-on-science-space-and-technology">Title IX - Committee On Science, Space, And Technology</a></li><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-1 menu__list-item"><a class="menu__link" href="/build-back-better-breakdown/docs/title-9-committee-on-transportation-and-infrastructure">Title XI - Committee On Transportation And Infrastructure</a></li><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-1 menu__list-item"><a class="menu__link" href="/build-back-better-breakdown/docs/title-12-committee-on-veterans-affairs">Title XII - Committee On Veterans Affairs</a></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-1 menu__list-item"><div class="menu__list-item-collapsible"><a class="menu__link menu__link--sublist menu__link--active hasHref_TwRn" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-a">Title XIII - Committee On Ways and Means</a></div><ul style="display:block;overflow:visible;height:auto" class="menu__list"><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-2 menu__list-item"><a class="menu__link" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-a">Subtitle A - Universal Paid Family and Medical Leave</a></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-2 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link hasHref_TwRn" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-b/">Subtitle B - Retirement</a><button aria-label="Toggle the collapsible sidebar category &#x27;Subtitle B - Retirement&#x27;" type="button" class="clean-btn menu__caret"></button></div></li><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-2 menu__list-item"><a class="menu__link" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-c">Subtitle C - Child Care Access and Equity</a></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-2 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link hasHref_TwRn" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-d/">Subtitle D - Trade Adjustment Assistance</a><button aria-label="Toggle the collapsible sidebar category &#x27;Subtitle D - Trade Adjustment Assistance&#x27;" type="button" class="clean-btn menu__caret"></button></div></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-2 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link menu__link--sublist hasHref_TwRn" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-e/title-13-subtitle-e-part-1">Subtitle E</a></div></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-2 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link hasHref_TwRn" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-f/">Subtitle F - Infrastructure Financing And Community Development</a><button aria-label="Toggle the collapsible sidebar category &#x27;Subtitle F - Infrastructure Financing And Community Development&#x27;" type="button" class="clean-btn menu__caret"></button></div></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-2 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link hasHref_TwRn" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-g/">Subtitle G - Green Energy</a><button aria-label="Toggle the collapsible sidebar category &#x27;Subtitle G - Green Energy&#x27;" type="button" class="clean-btn menu__caret"></button></div></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-2 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link hasHref_TwRn" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-h/">Subtitle H - Social Safety Net</a><button aria-label="Toggle the collapsible sidebar category &#x27;Subtitle H - Social Safety Net&#x27;" type="button" class="clean-btn menu__caret"></button></div></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-2 menu__list-item menu__list-item--collapsed"><div class="menu__list-item-collapsible"><a class="menu__link hasHref_TwRn" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-i/">Subtitle I - Responsibly Funding Our Priorities</a><button aria-label="Toggle the collapsible sidebar category &#x27;Subtitle I - Responsibly Funding Our Priorities&#x27;" type="button" class="clean-btn menu__caret"></button></div></li><li class="theme-doc-sidebar-item-category theme-doc-sidebar-item-category-level-2 menu__list-item"><div class="menu__list-item-collapsible"><a class="menu__link menu__link--sublist menu__link--active hasHref_TwRn" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-1">Subtitle J - Drug Pricing</a></div><ul style="display:block;overflow:visible;height:auto" class="menu__list"><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-3 menu__list-item"><a class="menu__link" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-1">Part 1 - Lowering Prices Through Fair Drug Price Negotiation</a></li><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-3 menu__list-item"><a class="menu__link menu__link--active" aria-current="page" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2">Part 2 - Prescription Drug Inflation Rebates</a></li><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-3 menu__list-item"><a class="menu__link" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-3">Part 3 - Part D Improvements And Maximum Out-Of-Pocket Cap For Medicare Beneficiaries</a></li><li class="theme-doc-sidebar-item-link theme-doc-sidebar-item-link-level-3 menu__list-item"><a class="menu__link" tabindex="0" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-4">Part 4 - Repeal Of Certain Prescription Drug Rebate Rule</a></li></ul></li></ul></li></ul></nav></div></aside><main class="docMainContainer_r8cw"><div class="container padding-top--md padding-bottom--lg"><div class="row"><div class="col docItemCol_zHA2"><div class="docItemContainer_oiyr"><article><div class="tocCollapsible_aw-L theme-doc-toc-mobile tocMobile_Tx6Y"><button type="button" class="clean-btn tocCollapsibleButton_zr6a">On this page</button></div><div class="theme-doc-markdown markdown"><header><h1>Part 2 - Prescription Drug Inflation Rebates</h1></header><h2 class="anchor anchorWithStickyNavbar_y2LR" id="sec-139101-medicare-part-b-rebate-by-manufacturers">SEC. 139101. MEDICARE PART B REBATE BY MANUFACTURERS.<a class="hash-link" href="#sec-139101-medicare-part-b-rebate-by-manufacturers" title="Direct link to heading">â€‹</a></h2><div class="codeBlockContainer_J+bg theme-code-block"><div class="codeBlockContent_csEI"><pre tabindex="0" class="prism-code language-undefined codeBlock_rtdJ thin-scrollbar" style="color:#393A34;background-color:#f6f8fa"><code class="codeBlockLines_1zSZ"><span class="token-line" style="color:#393A34"><span class="token plain">(a) In General.--Section 1834 of the Social Security Act (42 U.S.C. </span><br></span></code></pre><button type="button" aria-label="Copy code to clipboard" class="copyButton_M3SB clean-btn">Copy</button></div></div><p>1395m) is amended by adding at the end the following new subsection:
<code>(z) Rebate by Manufacturers for Single Source Drugs With Prices 
Increasing Faster Than Inflation.--
            </code>(1) Requirements.--
<code>(A) Secretarial provision of information.--Not 
                later than 6 months after the end of each calendar 
                quarter beginning on or after July 1, 2023, the 
                Secretary shall, for each part B rebatable drug, report 
                to each manufacturer of such part B rebatable drug the 
                following for such calendar quarter:
                            </code>(i) Information on the total number of
units of the billing and payment code described
in subparagraph (A)(i) of paragraph (3) with
respect to such drug and calendar quarter.
<code>(ii) Information on the amount (if any) 
                        of the excess average sales price increase 
                        described in subparagraph (A)(ii) of such 
                        paragraph for such drug and calendar quarter.
                            </code>(iii) The rebate amount specified under
such paragraph for such part B rebatable drug
and calendar quarter.
<code>(B) Manufacturer requirement.--For each calendar 
                quarter beginning on or after July 1, 2023, the 
                manufacturer of a part B rebatable drug shall, for such 
                drug, not later than 30 days after the date of receipt 
                from the Secretary of the information described in 
                subparagraph (A) for such calendar quarter, provide to 
                the Secretary a rebate that is equal to the amount 
                specified in paragraph (3) for such drug for such 
                calendar quarter.
            </code>(2) Part b rebatable drug defined.--
<code>(A) In general.--In this subsection, the term 
                `part B rebatable drug&#x27; means a single source drug or 
                biological (as defined in subparagraph (D) of section 
                1847A(c)(6)), including a biosimilar biological product 
                (as defined in subparagraph (H) of such section), 
                payable (if such drug were furnished to an individual 
                enrolled under this part) under this part, except such 
                term shall not include such a drug or biological--
                            </code>(i) if the average total allowed charges
under this part as determined by the Secretary
for a year per individual that uses such a drug
or biological, as determined by the Secretary,
are less than, subject to subparagraph (B),
$100; or
<code>(ii) that is a vaccine described in 
                        subparagraph (A) or (B) of section 1861(s)(10).
                    </code>(B) Increase.--The dollar amount applied under
subparagraph (A)(i)--
<code>(i) for 2024, shall be the dollar amount 
                        specified under such subparagraph for 2023, 
                        increased by the percentage increase in the 
                        consumer price index for all urban consumers 
                        (United States city average) for the 12-month 
                        period ending with June of the previous year; 
                        and
                            </code>(ii) for a subsequent year, shall be the
dollar amount specified in this clause (or
clause (i)) for the previous year, increased by
the percentage increase in the consumer price
index for all urban consumers (United States
city average) for the 12-month period ending
with June of the previous year.
Any dollar amount specified under this subparagraph
that is not a multiple of $10 shall be rounded to the
nearest multiple of $10.
<code>(3) Rebate amount.--
                    </code>(A) In general.--For purposes of paragraph (1),
the amount specified in this paragraph for a part B
rebatable drug assigned to a billing and payment code
for a calendar quarter is, subject to subparagraph (B)
and paragraph (4), the amount equal to the product of--
<code>(i) the total number of units, as 
                        described in section 1847A(c)(1)(B), with 
                        respect to such drug during the calendar 
                        quarter; and
                            </code>(ii) the amount (if any) by which--
<code>(I) the payment amount under 
                                subparagraph (B) or (C) of section 
                                1847A(b)(1), as applicable, for such 
                                part B rebatable drug during the 
                                calendar quarter; exceeds
                                    </code>(II) the inflation-adjusted
payment amount determined under
subparagraph (C) for such part B
rebatable drug during the calendar
quarter.
<code>(B) Excluded units.--For purposes of subparagraph 
                (A)(i), the Secretary shall exclude from the total 
                number of units with respect to a part B rebatable drug 
                and calendar quarter units of such part B rebatable 
                drug for which payment was made under a State plan 
                under title XIX (or waiver of such plan), as reported 
                by States under section 1927(b)(2)(A) for the most 
                recent rebate period.
                    </code>(C) Determination of inflation-adjusted payment
amount.--The inflation-adjusted payment amount
determined under this subparagraph for a part B
rebatable drug for a calendar quarter is--
<code>(i) the payment amount for the billing 
                        and payment code for such drug in the payment 
                        amount benchmark quarter (as defined in 
                        subparagraph (D)); increased by
                            </code>(ii) the percentage by which the rebate
period CPI-U (as defined in subparagraph (F))
for the calendar quarter exceeds the benchmark
period CPI-U (as defined in subparagraph (E)).
<code>(D) Payment amount benchmark quarter.--The term 
                `payment amount benchmark quarter&#x27; means the calendar 
                quarter beginning January 1, 2016.
                    </code>(E) Benchmark period cpi-u.--The term <code>benchmark 
                period CPI-U&#x27; means the consumer price index for all 
                urban consumers (United States city average) for July 
                2015.
                    ``(F) Rebate period cpi-u.--The term </code>rebate period
CPI-U&#x27; means, with respect to a calendar quarter
described in subparagraph (C), the greater of the
benchmark period CPI-U and the consumer price index for
all urban consumers (United States city average) for
the first month of the calendar quarter that is two
calendar quarters prior to such described calendar
quarter.
<code>(4) Special treatment of certain drugs and exemption.--
                    </code>(A) Subsequently approved drugs.--Subject to
subparagraph (B), in the case of a part B rebatable
drug first approved or licensed by the Food and Drug
Administration after July 1, 2015, clause (i) of
paragraph (3)(C) shall be applied as if the term
<code>payment amount benchmark quarter&#x27; were defined under 
                paragraph (3)(D) as the third full calendar quarter 
                after the day on which the drug was first marketed and 
                clause (ii) of paragraph (3)(C) shall be applied as if 
                the term </code>benchmark period CPI-U&#x27; were defined under
paragraph (3)(E) as if the reference to <code>July 2015&#x27; 
                under such paragraph were a reference to </code>the first
month of the first full calendar quarter after the day
on which the drug was first marketed&#x27;.
<code>(B) Timeline for provision of rebates for 
                subsequently approved drugs.--In the case of a part B 
                rebatable drug first approved or licensed by the Food 
                and Drug Administration after July 1, 2015, paragraph 
                (1)(B) shall be applied as if the reference to `July 1, 
                2023&#x27; under such paragraph were a reference to the 
                later of the 6th full calendar quarter after the day on 
                which the drug was first marketed or July 1, 2023.
                    </code>(C) Exemption for shortages.--The Secretary may
reduce or waive the rebate amount under paragraph
(1)(B) with respect to a part B rebatable drug that is
described as currently in shortage on the shortage list
in effect under section 506E of the Federal Food, Drug,
and Cosmetic Act or in the case of other exigent
circumstances, as determined by the Secretary.
<code>(D) Selected drugs.--In the case of a part B 
                rebatable drug that is a selected drug (as defined in 
                section 1192(c)) for a price applicability period (as 
                defined in section 1191(b)(2))--
                            </code>(i) for calendar quarters during such
period for which a maximum fair price (as
defined in section 1191(c)(2)) for such drug
has been determined and is applied under part E
of title XI, the rebate amount under paragraph
(1)(B) shall be waived; and
<code>(ii) in the case such drug is determined 
                        (pursuant to such section 1192(c)) to no longer 
                        be a selected drug, for each applicable year 
                        beginning after the price applicability period 
                        with respect to such drug, clause (i) of 
                        paragraph (3)(C) shall be applied as if the 
                        term `payment amount benchmark quarter&#x27; were 
                        defined under paragraph (3)(D) as the calendar 
                        quarter beginning January 1 of the last year 
                        beginning during such price applicability 
                        period with respect to such selected drug and 
                        clause (ii) of paragraph (3)(C) shall be 
                        applied as if the term `benchmark period CPI-U&#x27; 
                        were defined under paragraph (3)(E) as if the 
                        reference to `July 2015&#x27; under such paragraph 
                        were a reference to the July of the year 
                        preceding such last year.
            </code>(5) Application to beneficiary coinsurance.--In the case
of a part B rebatable drug, if the payment amount under this
part for a quarter exceeds the inflation adjusted payment for
such quarter--
<code>(A) in computing the amount of any coinsurance 
                applicable under this part to an individual to whom 
                such drug is furnished, the computation of such 
                coinsurance shall be based on the inflation-adjusted 
                payment amount determined under paragraph (3)(C) for 
                such part B rebatable drug; and
                    </code>(B) the amount of such coinsurance is equal to 20
percent of such inflation-adjusted payment amount so
determined.
<code>(6) Rebate deposits.--Amounts paid as rebates under 
        paragraph (1)(B) shall be deposited into the Federal 
        Supplementary Medical Insurance Trust Fund established under 
        section 1841.
            </code>(7) Civil money penalty.--If a manufacturer of a part B
rebatable drug has failed to comply with the requirements under
paragraph (1)(B) for such drug for a calendar quarter, the
manufacturer shall be subject to, in accordance with a process
established by the Secretary pursuant to regulations, a civil
money penalty in an amount equal to at least 125 percent of the
amount specified in paragraph (3) for such drug for such
calendar quarter. The provisions of section 1128A (other than
subsections (a) (with respect to amounts of penalties or
additional assessments) and (b)) shall apply to a civil money
penalty under this paragraph in the same manner as such
provisions apply to a penalty or proceeding under section
1128A(a).
<code>(8) Application to multiple source drugs.--The Secretary 
        may, pursuant to rulemaking, apply the provisions of this 
        subsection to multiple source drugs (as defined in section 
        1847A(c)(6)(C)), including, for purposes of determining the 
        rebate amount under paragraph (3), by calculating manufacturer-
        specific average sales prices for the benchmark period and the 
        rebate period.&#x27;&#x27;.
    (b) Amounts Payable; Cost-Sharing.--Section 1833 of the Social 
Security Act (42 U.S.C. 1395l) is amended--
            (1) in subsection (a)--
                    (A) in paragraph (1)--
                            (i) in subparagraph (G), by inserting </code>,
subject to subsection (i)(9),&#x27;&#x27; after <code>the 
                        amounts paid&#x27;&#x27;;
                            (ii) in subparagraph (S), by striking 
                        </code>with respect to&#x27;&#x27; and inserting <code>subject to 
                        subparagraph (DD), with respect to&#x27;&#x27;;
                            (iii) by striking </code>and (DD)&#x27;&#x27; and
inserting <code>(EE)&#x27;&#x27;; and
                            (iv) by inserting before the semicolon at 
                        the end the following: </code>, and (EE) with
respect to a part B rebatable drug (as defined
in paragraph (2) of section 1834(z)) for which
the payment amount for a calendar quarter under
paragraph (3)(A)(ii)(I) of such section for
such quarter exceeds the inflation-adjusted
payment under paragraph (3)(A)(ii)(II) of such
section for such quarter, the amounts paid
shall be the difference between (i) the payment
amount under paragraph (3)(A)(ii)(I) of such
section for such drug, and (ii) 20 percent of
the inflation-adjusted payment amount under
paragraph (3)(A)(ii)(II) of such section for
such drug&#x27;&#x27;; and
(B) by adding at the end of the flush left matter
following paragraph (9), the following:
<code>For purposes of applying paragraph (1)(EE), subsections (i)(9) and 
(t)(8)(F), and section 1834(z)(5), the Secretary shall make such 
estimates and use such data as the Secretary determines appropriate, 
and may do so by program instruction or otherwise.&#x27;&#x27;;
            (2) in subsection (i), by adding at the end the following 
        new paragraph:
    </code>(9) In the case of a part B rebatable drug (as defined in
paragraph (2) of section 1834(z)) for which payment under this
subsection is not packaged into a payment for a covered OPD service (as
defined in subsection (t)(1)(B)) (or group of services) furnished on or
after July 1, 2023, under the system under this subsection, in lieu of
calculation of coinsurance and the amount of payment otherwise
applicable under this subsection, the provisions of section 1834(z)(5),
paragraph (1)(EE) of subsection (a), and the flush left matter
following paragraph (9) of subsection (a), shall, as determined
appropriate by the Secretary, apply under this subsection in the same
manner as such provisions of section 1834(z)(5) and subsection (a)
apply under such section and subsection.&#x27;&#x27;; and
(3) in subsection (t)(8), by adding at the end the
following new subparagraph:
<code>(F) Part b rebatable drugs.--In the case of a 
                part B rebatable drug (as defined in paragraph (2) of 
                section 1834(z)) for which payment under this part is 
                not packaged into a payment for a service furnished on 
                or after July 1, 2023, under the system under this 
                subsection, in lieu of calculation of coinsurance and 
                the amount of payment otherwise applicable under this 
                subsection, the provisions of section 1834(z)(5), 
                paragraph (1)(EE) of subsection (a), and the flush left 
                matter following paragraph (9) of subsection (a), 
                shall, as determined appropriate by the Secretary, 
                apply under this subsection in the same manner as such 
                provisions of section 1834(z)(5) and subsection (a) 
                apply under such section and subsection.&#x27;&#x27;.
    (c) Conforming Amendments.--
            (1) To part b asp calculation.--Section 1847A(c)(3) of the 
        Social Security Act (42 U.S.C. 1395w-3a(c)(3)) is amended by 
        inserting </code>or section 1834(z)&#x27;&#x27; after <code>section 1927&#x27;&#x27;.
            (2) Excluding parts b drug inflation rebate from best 
        price.--Section 1927(c)(1)(C)(ii)(I) of the Social Security Act 
        (42 U.S.C. 1396r-8(c)(1)(C)(ii)(I)) is amended by inserting 
        </code>or section 1834(z)&#x27;&#x27; after <code>this section&#x27;&#x27;.
            (3) Coordination with medicaid rebate information 
        disclosure.--Section 1927(b)(3)(D)(i) of the Social Security 
        Act (42 U.S.C. 1396r-8(b)(3)(D)(i)) is amended by striking </code>or
to carry out section 1847B&#x27;&#x27; and inserting ``to carry out
section 1847B or section 1834(z)&#x27;&#x27;.</p><p>SEC. 139102. MEDICARE PART D REBATE BY MANUFACTURERS.</p><div class="codeBlockContainer_J+bg theme-code-block"><div class="codeBlockContent_csEI"><pre tabindex="0" class="prism-code language-undefined codeBlock_rtdJ thin-scrollbar" style="color:#393A34;background-color:#f6f8fa"><code class="codeBlockLines_1zSZ"><span class="token-line" style="color:#393A34"><span class="token plain">(a) In General.--Part D of title XVIII of the Social Security Act </span><br></span></code></pre><button type="button" aria-label="Copy code to clipboard" class="copyButton_M3SB clean-btn">Copy</button></div></div><p>is amended by inserting after section 1860D-14A (42 U.S.C. 1395w-114a)
the following new section:</p><p>``SEC. 1860D-14B. MANUFACTURER REBATE FOR CERTAIN DRUGS WITH PRICES
INCREASING FASTER THAN INFLATION.</p><div class="codeBlockContainer_J+bg theme-code-block"><div class="codeBlockContent_csEI"><pre tabindex="0" class="prism-code language-undefined codeBlock_rtdJ thin-scrollbar" style="color:#393A34;background-color:#f6f8fa"><code class="codeBlockLines_1zSZ"><span class="token-line" style="color:#393A34"><span class="token plain">``(a) Requirements.--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">        ``(1) Secretarial provision of information.--Not later than </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    9 months after the end of each applicable year (as defined in </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    subsection (g)(7)), the Secretary shall, for each part D </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    rebatable drug, report to each manufacturer of such part D </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    rebatable drug the following for such year:</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(A) Information on the amount (if any) of the </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            excess average manufacturer price increase described in </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            subsection (b)(1)(B) for each dosage form and strength </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            with respect to such drug and year.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(B) The rebate amount specified under subsection </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            (b) for each dosage form and strength with respect to </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            such drug and year.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">        ``(2) Manufacturer requirements.--For each applicable year, </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    the manufacturer of a part D rebatable drug, for each dosage </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    form and strength with respect to such drug, not later than 30 </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    days after the date of receipt from the Secretary of the </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    information described in paragraph (1) for such year, shall </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    provide to the Secretary a rebate that is equal to the amount </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    specified in subsection (b) for such dosage form and strength </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    with respect to such drug for such year.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">``(b) Rebate Amount.--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">        ``(1) In general.--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(A) Calculation.--For purposes of this section, </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            the amount specified in this subsection for a dosage </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            form and strength with respect to a part D rebatable </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            drug and applicable year is, subject to subparagraph </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            (B) of this paragraph and subparagraphs (B) and (C) of </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            paragraph (5), the amount equal to the product of--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                        ``(i) the total number of units that are </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    used to calculate the average manufacturer </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    price of such dosage form and strength with </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    respect to such part D rebatable drug, as </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    reported by the manufacturer of such drug under </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    section 1927 for each recent rebate period </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    under such section, with respect to such year, </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    under such section for which such information </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    is available; and</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                        ``(ii) the amount (if any) by which--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                                ``(I) the annual manufacturer price </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                            (as determined in paragraph (2)) paid </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                            for such dosage form and strength with </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                            respect to such part D rebatable drug </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                            for the year; exceeds</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                                ``(II) the inflation-adjusted </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                            payment amount determined under </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                            paragraph (3) for such dosage form and </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                            strength with respect to such part D </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                            rebatable drug for the year.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(B) Excluded units.--For purposes of subparagraph </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            (A)(i), the Secretary shall exclude from the total </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            number of units for a dosage form and strength with </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            respect to a part D rebatable drug and the most recent </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            rebate period under section 1927, with respect to an </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            applicable year, for which such information is </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            available, units of each dosage form and strength of </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            such part D rebatable drug, for which payment was made </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            under a State plan under title XIX (or waiver of such </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            plan), as reported by States under section </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            1927(b)(2)(A) for such rebate period.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">        ``(2) Determination of annual manufacturer price.--The </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    annual manufacturer price determined under this paragraph for a </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    dosage form and strength, with respect to a part D rebatable </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    drug and an applicable year, is the sum of the products of--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(A) the average manufacturer price (as defined in </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            subsection (g)(6)) of such dosage form and strength, as </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            calculated for a unit of such drug, with respect to </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            each of the calendar quarters of such year; and</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(B) the ratio of--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                        ``(i) the total number of units of such </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    dosage form and strength reported for the </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    purpose of calculating average manufacturer </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    price under section 1927 during each such </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    calendar quarter of such year; to</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                        ``(ii) the total number of units of such </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    dosage form and strength reported for the </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    purpose of calculating average manufacturer </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    price under section 1927 during such year, as </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    determined by the Secretary.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">        ``(3) Determination of inflation-adjusted payment amount.--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    The inflation-adjusted payment amount determined under this </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    paragraph for a dosage form and strength with respect to a part </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    D rebatable drug for an applicable year, subject to </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    subparagraphs (A) and (D) of paragraph (5), is--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(A) the benchmark year manufacturer price </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            determined under paragraph (4) for such dosage form and </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            strength with respect to such drug and year; increased </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            by</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(B) the percentage by which the applicable year </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            CPI-U (as defined in subsection (g)(5)) for the year </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            exceeds the benchmark period CPI-U (as defined in </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            subsection (g)(4)).</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">        ``(4) Determination of benchmark year manufacturer price.--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    The benchmark year manufacturer price determined under this </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    paragraph for a dosage form and strength, with respect to a </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    part D rebatable drug and an applicable year, is the sum of the </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">    products of--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(A) the average manufacturer price (as defined in </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            subsection (g)(6)) of such dosage form and strength, as </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            calculated for a unit of such drug, with respect to </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            each of the calendar quarters of the payment amount </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            benchmark year (as defined in subsection (g)(3)); and</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(B) the ratio of--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                        ``(i) the total number of units of such </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    dosage form and strength dispensed during each </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    such calendar quarter of such payment amount </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    benchmark year; to</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                        ``(ii) the total number of units of such </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    dosage form and strength dispensed during such </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    payment amount benchmark year.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">        ``(5) Special treatment of certain drugs and exemption.--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(A) Subsequently approved drugs.--In the case of </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            a part D rebatable drug first approved or licensed by </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            the Food and Drug Administration after January 1, 2016, </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            subparagraphs (A) and (B) of paragraph (4) shall be </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            applied as if the term `payment amount benchmark year&#x27; </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            were defined under subsection (g)(3) as the first </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            calendar year beginning after the day on which the drug </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            was first marketed by any manufacturer and subparagraph </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            (B) of paragraph (3) shall be applied as if the term </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            `benchmark period CPI-U&#x27; were defined under subsection </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            (g)(4) as if the reference to `January 2016&#x27; under such </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            subsection were a reference to `January of the first </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            year beginning after the date on which the drug was </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            first marketed by any manufacturer&#x27;.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(B) Exemption for shortages.--The Secretary may </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            reduce or waive the rebate under paragraph (1) with </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            respect to a part D rebatable drug that is described as </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            currently in shortage on the shortage list in effect </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            under section 506E of the Federal Food, Drug, and </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            Cosmetic Act or in the case of other exigent </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            circumstances, as determined by the Secretary.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(C) Treatment of new formulations.--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                        ``(i) In general.--In the case of a part D </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    rebatable drug that is a line extension of a </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    part D rebatable drug that is an oral solid </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    dosage form, the Secretary shall establish a </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    formula for determining the amount specified in </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    this subsection with respect to such part D </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    rebatable drug and an applicable year with </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    consideration of the original part D rebatable </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    drug.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                        ``(ii) Line extension defined.--In this </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    subparagraph, the term `line extension&#x27; means, </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    with respect to a part D rebatable drug, a new </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    formulation of the drug, such as an extended </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    release formulation, but does not include an </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    abuse-deterrent formulation of the drug (as </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    determined by the Secretary), regardless of </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    whether such abuse-deterrent formulation is an </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    extended release formulation.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                ``(D) Selected drugs.--In the case of a part D </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            rebatable drug that is a selected drug (as defined in </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            section 1192(c)) for a price applicability period (as </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">            defined in section 1191(b)(2))--</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                        ``(i) for plan years during such period for </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    which a maximum fair price (as defined in </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    section 1191(c)(2)) for such drug has been </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    determined and is applied under part E of title </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    XI, the rebate under subsection (a)(1)(B) shall </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    be waived; and</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                        ``(ii) in the case such drug is determined </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    (pursuant to such section 1192(c)) to no longer </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    be a selected drug, for each applicable year </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    beginning after the price applicability period </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    with respect to such drug, subparagraphs (A) </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    and (B) of paragraph (4) shall be applied as if </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    the term `payment amount benchmark year&#x27; were </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    defined under subsection (g)(3) as the last </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    year beginning during such price applicability </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    period with respect to such selected drug and </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    subparagraph (B) of paragraph (3) shall be </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    applied as if the term `benchmark period CPI-U&#x27; </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    were defined under subsection (g)(4) as if the </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    reference to `January 2016&#x27; under such </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    subsection were a reference to January of the </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    last year beginning during such price </span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">                    applicability period with respect to such drug.</span><br></span><span class="token-line" style="color:#393A34"><span class="token plain">``(c) Rebate Deposits.--Amounts paid as rebates under subsection </span><br></span></code></pre><button type="button" aria-label="Copy code to clipboard" class="copyButton_M3SB clean-btn">Copy</button></div></div><p>(b) shall be deposited into the Medicare Prescription Drug Account in
the Federal Supplementary Medical Insurance Trust Fund established
under section 1841.
<code>(d) Information.--For purposes of carrying out this section, the 
Secretary shall use information submitted by manufacturers under 
section 1927(b)(3) and information submitted by States under section 
1927(b)(2)(A).
    </code>(e) Civil Money Penalty.--If a manufacturer of a part D rebatable
drug has failed to comply with the requirement under subsection
(a)(1)(B) with respect to such drug for an applicable year, the
manufacturer shall be subject to, in accordance with a process
established by the Secretary pursuant to regulations, a civil money
penalty in an amount equal to 125 percent of the amount specified in
subsection (b) for such drug for such year. The provisions of section
1128A (other than subsections (a) (with respect to amounts of penalties
or additional assessments) and (b)) shall apply to a civil money
penalty under this subsection in the same manner as such provisions
apply to a penalty or proceeding under section 1128A(a).
<code>(f) Judicial Review.--There shall be no judicial review of the 
following:
            </code>(1) The determination of units under this section.
<code>(2) The determination of whether a drug is a part D 
        rebatable drug under this section.
            </code>(3) The calculation of the rebate amount under this
section.
<code>(g) Definitions.--In this section:
            </code>(1) Part d rebatable drug defined.--
<code>(A) In general.--The term `part D rebatable drug&#x27; 
                means a drug or biological that would (without 
                application of this section) be a covered part D drug, 
                except such term shall, with respect to an applicable 
                year, not include such a drug or biological if the 
                average annual total cost under this part for such year 
                per individual who uses such a drug or biological, as 
                determined by the Secretary, is less than, subject to 
                subparagraph (B), $100, as determined by the Secretary 
                using the most recent data available or, if data is not 
                available, as estimated by the Secretary.
                    </code>(B) Increase.--The dollar amount applied under
subparagraph (A)--
<code>(i) for 2024, shall be the dollar amount 
                        specified under such subparagraph for 2023, 
                        increased by the percentage increase in the 
                        consumer price index for all urban consumers 
                        (United States city average) for the 12-month 
                        period beginning with January of 2023; and
                            </code>(ii) for a subsequent year, shall be the
dollar amount specified in this subparagraph
for the previous year, increased by the
percentage increase in the consumer price index
for all urban consumers (United States city
average) for the 12-month period beginning with
January of the previous year.
Any dollar amount specified under this subparagraph
that is not a multiple of $10 shall be rounded to the
nearest multiple of $10.
<code>(2) Unit defined.--The term `unit&#x27; means, with respect to 
        a part D rebatable drug, the lowest identifiable quantity (such 
        as a capsule or tablet, milligram of molecules, or grams) of 
        the part D rebatable drug, including data reported under 
        section 1927.
            </code>(3) Payment amount benchmark year.--The term <code>payment 
        amount benchmark year&#x27; means the year beginning January 1, 
        2016.
            ``(4) Benchmark period cpi-u.--The term </code>benchmark period
CPI-U&#x27; means the consumer price index for all urban consumers
(United States city average) for January 2016.
<code>(5) Applicable year cpi-u.--The term `applicable year 
        CPI-U&#x27; means, with respect to an applicable year, the consumer 
        price index for all urban consumers (United States city 
        average) for January of such year.
            </code>(6) Average manufacturer price.--The term <code>average 
        manufacturer price&#x27; has the meaning, with respect to a part D 
        rebatable drug of a manufacturer, given such term in section 
        1927(k)(1), with respect to a covered outpatient drug of a 
        manufacturer for a rebate period under section 1927.
            ``(7) Applicable year.--The term </code>applicable year&#x27; means a
year beginning with 2023.&#x27;&#x27;.
(b) Conforming Amendments.--
(1) To part b asp calculation.--Section 1847A(c)(3) of the
Social Security Act (42 U.S.C. 1395w-3a(c)(3)), as amended by
section 139101(c)(1), is further amended by striking <code>section 
        1927 or section 1834(z)&#x27;&#x27; and inserting </code>section 1927, section
1834(z), or section 1860D-14B&#x27;&#x27;.
(2) Excluding part d drug inflation rebate from best
price.--Section 1927(c)(1)(C)(ii)(I) of the Social Security Act
(42 U.S.C. 1396r-8(c)(1)(C)(ii)(I)), as amended by section
139101(c)(2), is further amended by striking <code>or section 
        1834(z)&#x27;&#x27; and inserting </code>, section 1834(z), or section 1860D-
14B&#x27;&#x27;.
(3) Coordination with medicaid rebate information
disclosure.--Section 1927(b)(3)(D)(i) of the Social Security
Act (42 U.S.C. 1396r-8(b)(3)(D)(i)), as amended by section
139101(c)(3), is further amended by striking <code>or section 
        1834(z)&#x27;&#x27; and inserting </code>, section 1834(z), or section 1860D-
14B&#x27;&#x27;.</p></div><footer class="theme-doc-footer docusaurus-mt-lg"><div class="theme-doc-footer-edit-meta-row row"><div class="col"><a href="https://github.com/EdwardAngert/build-back-better-breakdown/tree/main/packages/create-docusaurus/templates/shared/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-2.md" target="_blank" rel="noreferrer noopener" class="theme-edit-this-page"><svg fill="currentColor" height="20" width="20" viewBox="0 0 40 40" class="iconEdit_mS5F" aria-hidden="true"><g><path d="m34.5 11.7l-3 3.1-6.3-6.3 3.1-3q0.5-0.5 1.2-0.5t1.1 0.5l3.9 3.9q0.5 0.4 0.5 1.1t-0.5 1.2z m-29.5 17.1l18.4-18.5 6.3 6.3-18.4 18.4h-6.3v-6.2z"></path></g></svg>Edit this page</a></div><div class="col lastUpdated_mt2f"></div></div></footer></article><nav class="pagination-nav docusaurus-mt-lg" aria-label="Docs pages navigation"><div class="pagination-nav__item"><a class="pagination-nav__link" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-1"><div class="pagination-nav__sublabel">Previous</div><div class="pagination-nav__label">Part 1 - Lowering Prices Through Fair Drug Price Negotiation</div></a></div><div class="pagination-nav__item pagination-nav__item--next"><a class="pagination-nav__link" href="/build-back-better-breakdown/docs/title-13-committee-on-ways-and-means/title-13-subtitle-j/title-13-subtitle-j-part-3"><div class="pagination-nav__sublabel">Next</div><div class="pagination-nav__label">Part 3 - Part D Improvements And Maximum Out-Of-Pocket Cap For Medicare Beneficiaries</div></a></div></nav></div></div><div class="col col--3"><div class="tableOfContents_vrFS thin-scrollbar theme-doc-toc-desktop"><ul class="table-of-contents table-of-contents__left-border"><li><a href="#sec-139101-medicare-part-b-rebate-by-manufacturers" class="table-of-contents__link toc-highlight">SEC. 139101. MEDICARE PART B REBATE BY MANUFACTURERS.</a></li></ul></div></div></div></div></main></div></div><footer class="footer footer--dark"><div class="container container-fluid"><div class="row footer__links"><div class="col footer__col"><div class="footer__title">H.R.5376</div><ul class="footer__items"><li class="footer__item"><a class="footer__link-item" href="/build-back-better-breakdown/docs/intro">Explore the Act</a></li></ul></div><div class="col footer__col"><div class="footer__title">More</div><ul class="footer__items"><li class="footer__item"><a href="https://github.com/EdwardAngert/build-back-better-breakdown/discussions" target="_blank" rel="noopener noreferrer" class="footer__link-item">Discussions</a></li><li class="footer__item"><a href="https://github.com/EdwardAngert/build-back-better-breakdown" target="_blank" rel="noopener noreferrer" class="footer__link-item"><span>GitHub<svg width="13.5" height="13.5" aria-hidden="true" viewBox="0 0 24 24" class="iconExternalLink_wgqa"><path fill="currentColor" d="M21 13v10h-21v-19h12v2h-10v15h17v-8h2zm3-12h-10.988l4.035 4-6.977 7.07 2.828 2.828 6.977-7.07 4.125 4.172v-11z"></path></svg></span></a></li></ul></div></div><div class="footer__bottom text--center"><div class="footer__copyright">Copyright Â© 2022 My Project, Inc. Built with Docusaurus.</div></div></div></footer></div>
<script src="/build-back-better-breakdown/assets/js/runtime~main.f44b3b35.js"></script>
<script src="/build-back-better-breakdown/assets/js/main.5dd824db.js"></script>
</body>
</html>